At present, acetylcholinesterase (AChE) inhibitors, N-methyl-D-aspartate (NMDA) receptor antagonists or a combination of them are used clinically to increase the content of neurotransmitters in the synaptic space to alleviate cognitive and behavioral disorders [8]. This evidence concerns the gene ACHE and Atypical behavior.